Global Blood Therapeutics, Inc. GBT
Set alert
68.49 +68.49 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -29.14
- Beta
- 0.46
- Short ratio
- 2.11
- Inst. own
- 111.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2022
- 50-d avg
- 63.70
- 200-d avg
- 38.56
- 1y target
- 64.50
Analyst view
Consensus: buy
Buy
Price target (mean) 64.50 -5.8% downside
Now 68.49
- Target (low)
- 60.00
- Target (mean)
- 64.50
- Target (high)
- 68.50
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy4
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 18
- 2 months ago 21
- 3 months ago 19
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.06 | -1.06 – -1.06 | -1.13 | +6.2% | 71.03M | 0.0% | 1 |
| Next quarter | -0.72 | -0.72 – -0.72 | -1.36 | +47.1% | 93.76M | +67.1% | 1 |
| Current year | -4.17 | -4.17 – -4.17 | -4.81 | +13.3% | 284.11M | +45.9% | 1 |
| Next year | -2.35 | -2.35 – -2.35 | -4.17 | +43.6% | 457.42M | +61.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2022 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Aug 9, 2022 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Aug 9, 2022 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Aug 9, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 9, 2022 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Aug 8, 2022 | Stifel | Downgrade | Buy | Hold |
| Aug 8, 2022 | Wedbush | Downgrade | Outperform | Neutral |
| Aug 8, 2022 | Jefferies | Downgrade | Buy | Hold |
| Aug 8, 2022 | Canaccord Genuity | Upgrade | Hold | Buy |
| Jun 28, 2022 | JP Morgan | Maintained | — | Neutral |
| May 5, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 28, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 24, 2022 | Oppenheimer | Maintained | — | Outperform |
| Dec 21, 2021 | SVB Leerink | Maintained | — | Outperform |
| Dec 14, 2021 | SVB Leerink | Maintained | — | Outperform |
| Dec 7, 2021 | William Blair | Upgrade | Market Perform | Outperform |
| Nov 5, 2021 | RBC Capital | Maintained | — | Outperform |
| Oct 7, 2021 | Jefferies | Initiated | — | Buy |
| Aug 4, 2021 | Truist Securities | Upgrade | Hold | Buy |
| Jun 28, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| May 6, 2021 | Canaccord Genuity | Maintained | — | Hold |
| May 6, 2021 | Roth Capital | Maintained | — | Buy |
| Apr 14, 2021 | SVB Leerink | Initiated | — | Outperform |
| Mar 12, 2021 | Wolfe Research | Initiated | — | Outperform |
| Jan 20, 2021 | Piper Sandler | Downgrade | Overweight | Neutral |
| Dec 16, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Dec 3, 2020 | RBC Capital | Initiated | — | Outperform |
| Nov 6, 2020 | Canaccord Genuity | Maintained | — | Hold |
| Nov 6, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Nov 6, 2020 | Roth Capital | Maintained | — | Buy |